Form 4: Precision BioSciences Director Stanley Frankel Acquires Restricted Stock Units

Director Stanley Frankel acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences on June 4, 2024.

Summary

• On June 4, 2024, Stanley Frankel, a director of Precision BioSciences, acquired 9,826 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Precision BioSciences' Common Stock or an equivalent cash amount.
• The RSUs will vest on the earlier of June 4, 2025, or the day before the next annual meeting of stockholders, contingent upon Frankel's continued service to the Issuer.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard filing indicating insider transactions. The acquisition of RSUs can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon Stanley Frankel's continued service to Precision BioSciences.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates